Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$1.02
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.02
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$0.42 - $7.19
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$12.69M
Enterprise Value-$5.73M
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$757.00K
Price to Earnings (P/E)―
Beta2.67
Next Earnings
Aug 07, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.40
Shares Outstanding28,009,802
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit272.64
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$7.88Price Target Upside672.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute LeverageVery low absolute debt reduces interest and covenant pressure, preserving near-term financial flexibility. For a pre-revenue biotech this limits mandatory cash outflows and keeps financing and partnership options open over the next several months, supporting operational continuity.
Focused Clinical PipelineA concentrated, disease-focused pipeline provides a clear strategic identity and endpoint-driven development path. Specialization in mast cell biology can create defensible scientific differentiation and make targeted partnerships or licensing more likely if clinical data are supportive.
Strengthened Financial OversightAdding experienced audit oversight improves governance and financial controls, which enhances credibility with investors, partners and potential acquirers. Stronger audit committee oversight is a durable governance improvement that reduces execution and reporting risk over the medium term.
Bears Say
High Cash BurnSustained negative operating and free cash flow creates ongoing financing needs and increases the likelihood of dilution or deal-driven strategic choices. Persistent burn limits runway, pressures cost reductions, and is a durable constraint on execution absent revenue or substantial financing.
Pre-Revenue ProfileWithout commercial revenue the company remains entirely dependent on clinical progress and external capital. This structural lack of earnings means margins, cash generation and valuation are contingent on binary clinical and financing outcomes over the medium term.
Strategic Review Includes Wind-DownAn active strategic review that explicitly contemplates a wind-down signals material uncertainty about viability absent a transaction or funding. This raises the probability of non-operational outcomes and constrains long-term planning, partner talks and employee retention.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.42 and its highest was $7.19 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $12.69M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 47 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on May 14, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.446.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 28,009,802 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went down -11.366%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematopoietic stem cell transplantation and gene therapies. Its core mission is to develop and commercialize conditioning agents and advanced stem cell engineering methods. These advancements aim to expand the utility of stem cell transplantation and ex vivo gene therapy, a process involving genetic modification of cells outside the body before their transplantation. JSP191 stands as the company's leading investigational product, currently in clinical development. This conditioning antibody functions by ablating hematopoietic stem cells from patients' bone marrow as a prerequisite for allogeneic stem cell or stem cell gene therapy. Additionally, Jasper is creating engineered hematopoietic stem cell product candidates intended to address significant limitations inherent in both allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$7.88
▲(672.06% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
5.12% Mutual Funds
33.45% Other Institutional Investors
55.76% Public Companies and
Individual Investors